University of Michigan, 1997, B.S.E. Materials Science and Engineering
University of Michigan, 2005, Ph.D. Biomedical Engineering
His research interests include molecular imaging of bone structure, metabolism, and skeletal drug delivery, osteogenesis imperfecta, resulting bone fragility, and therapeutic options, assessment of bone quality measures beyond bone mineral density, regulators of bone metabolism and bone mass, interaction between bone drugs and microdamage, fracture susceptibility and repair, and role of aerobic metabolism in bone cell function and skeletal phenotype
Sinder BP, White LE, Salemi JD, Ominsky MS, Caird MS, Marini JC, Kozloff KM: Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength. Osteoporosis International 25(8): 2097-2107, 2014.
Jepsen KJ, Schlecht SH, Kozloff KM: Are we taking full advantage of the growing number of pharmacological treatment options for osteoporosis? Current Opinions in Pharmacology 16: 64-71, 2014.
Perosky JE, Peterson JR, Eboda ON, Morris MD, Wang SC, Levi B, Kozloff KM: Early detection of heterotopic ossification using near-infrared optical imaging reveals dynamic turnover and progression of mineralization following achilles tenotomy and burn injury. Journal of Orthopaedic Research 32(11): 1416-1423, 2014.
Sinder BP, Salemi JD, Caird MS, Marini JC, Kozloff KM: Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment. Bone 71: 115-23, 2015.